BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Dependable Savvy Locks to Update Your Home Security - 2Well known SUVs With Low Energy Utilization In 2024
- 3Most loved Occasion Dish: What Makes Your Merry Table?
- 4Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
- 5Top 10 Books That Will Adjust Your Viewpoint
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- Top Frozen yogurt Flavor: Cast Your Vote!
- Figure out How to Adjust Your Handshake to Various Societies
- 7 Logically Demonstrated Techniques for Better Rest
- Figure out How to Remain Persuaded During Your Internet based Degree Program
- Vote In favor of Your Favored Web-based Visual depiction Administration
- 5 Home EV Chargers for Proficient and Solid Charging
- Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
